Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Oct;5(5):e000633.
doi: 10.1136/esmoopen-2019-000633.

FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?

Angela Lamarca  1 , Lucy Foster  2 , Juan W Valle  3 , Thomas Satyadas  4 , Ajith Siriwardena  4
Affiliations
Editorial

FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?

Angela Lamarca et al. ESMO Open. 2020 Oct.

Erratum in

No abstract available

Keywords: FOLFIRINOX; FOLFOXIRIx; chemotherapy; duodenal cancer; small bowel.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Summary of radiological and pathology findings before and after FOLFIRINOX chemotherapy (case 1). (A) CT scan showed primary tumour arising from the duodenum (green), locally advanced and unresectable in view of superior mesenteric artery (SMA) involvement (red); presence of duodenal stent (purple arrow). (B) Pre-chemotherapy biopsy confirmed diagnosis of adenocarcinoma. (C) After 6 months of FOLFIRINOX chemotherapy, CT confirmed reduction in size of the primary tumour (green), with cuff of tissue surrounding the SMA being less solid in appearance (red) and not infiltrated by tumour; duodenal stent still in situ (purple arrow). (D) Complete pathological response was identified in Whipple resection specimen with no evidence of residual disease.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34. 10.3322/caac.21551 - DOI - PubMed
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29. 10.3322/caac.20138 - DOI - PubMed
    1. Bilimoria KY, Bentrem DJ, Wayne JD, et al. . Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009;249:63–71. 10.1097/SLA.0b013e31818e4641 - DOI - PubMed
    1. Locher C, Batumona B, Afchain P, et al. . Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis 2018;50:15–19. 10.1016/j.dld.2017.09.123 - DOI - PubMed
    1. Schrock AB, Devoe CE, McWilliams R, et al. . Genomic profiling of small-bowel adenocarcinoma. JAMA Oncol 2017;3:1546–53. 10.1001/jamaoncol.2017.1051 - DOI - PMC - PubMed

Publication types

Supplementary concepts